Trial Profile
Phase 1, First in Human Study to Evaluate the Safety, Tolerability and Immunogenicity of Ad35.RSV.FA2 Regimens Boosted With Ad26.RSV.FA2 in Healthy Adult Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 24 Aug 2017
Price :
$35
*
At a glance
- Drugs JNJ 61187191 (Primary)
- Indications Respiratory syncytial virus infections
- Focus Adverse reactions
- Sponsors Crucell Holland
- 22 Aug 2016 Status changed from recruiting to completed.
- 25 May 2015 New trial record